AMGEN Inc NASDAQ:AMGN Price, Chart, News & Insight

Amgen and AstraZeneca Report Positive Phase 3 TEZSPIRE Results in Eosinophilic Esophagitis

Amgen (NASDAQ: AMGN) and AstraZeneca reported positive Phase 3 results for TEZSPIRE in patients with eosinophilic esophagitis (EoE), potentially opening another major indication for the drug.

In the CROSSING trial, TEZSPIRE achieved statistically significant and clinically meaningful improvements across both co-primary endpoints — histologic remission and the frequency and severity of difficulty swallowing — at Week 24. The benefits were sustained through Week 52, while the safety profile remained generally consistent with TEZSPIRE’s currently approved indications.

The Phase 3 trial enrolled 368 adults and adolescents with symptomatic, active EoE and compared two TEZSPIRE doses with placebo. Full results will be presented at an upcoming medical meeting and submitted to regulatory authorities.

The results are strategically important because EoE would represent a third epithelial-driven inflammatory disease in which TEZSPIRE has demonstrated efficacy. The drug is already approved for severe asthma and inadequately controlled chronic rhinosinusitis with nasal polyps in several major markets.

💬

Global Finance News 08-27-26

Amgen Stock Rises 2.7% as Argus Raises Price Target and Morgan Stanley Reiterates Overweight

Amgen (NASDAQ: AMGN) shares are up about 2.7% following positive analyst actions from Argus and Morgan Stanley, adding to bullish sentiment around the biotechnology company.

Argus analyst Jasper Hellweg raised the firm's price target on Amgen to $460 from $375 while maintaining a Buy rating. The new target represents roughly 5% upside from the stock's current price of $436.60.

Morgan Stanley analyst Terence Flynn also reiterated an Overweight rating on Amgen. Although the displayed $362 price target is below the current share price, the continued Overweight recommendation provides another positive signal on the company's broader outlook.

Amgen is one of the world's largest biotechnology companies, with a diversified portfolio spanning oncology, cardiovascular disease, inflammation and rare diseases. Its scale, established product portfolio and pipeline provide a relatively defensive position within the biotech sector, while newer products and pipeline development offer additional growth opportunities.

The 2.7% gain appears supported by the combination of Argus' substantial price-target increase and Morgan Stanley's reiterated bullish rating, with Argus' move particularly notable given the increase from $375 to $460.

💬

Global Finance News 08-19-26

Amgen Stock Edges Higher After Strong Q2 Earnings as Growth Portfolio Drives Double-Digit Revenue Increase

Amgen (NASDAQ: AMGN) shares rose about 1% in after-hours trading on Tuesday after the biotechnology company reported stronger second-quarter results, supported by broad-based product growth, expanding profitability, and solid cash generation.

Second-quarter revenue increased 10% year over year to $10.1 billion, while product sales climbed 9% on higher volumes. GAAP earnings per share surged 65% to $4.37, and non-GAAP EPS increased 4% to $6.29, exceeding the prior year's performance despite higher research and operating expenses. The company also generated $3.5 billion in free cash flow during the quarter, nearly doubling from a year earlier.

Growth was driven by Amgen's expanding portfolio, with six key growth products collectively rising 26% year over year and accounting for nearly 70% of total product sales. Twenty-two products delivered double-digit sales growth, while seventeen products are now generating annualized sales exceeding $1 billion.

Several blockbuster medicines posted particularly strong results. Repatha sales jumped 37%, EVENITY climbed 38%, TEZSPIRE gained 42%, and rare disease therapies continued to perform well, led by UPLIZNA, whose sales surged 90%. Oncology products also remained a key growth driver, with IMDELLTRA sales more than doubling, while BLINCYTO, Nplate, Vectibix and LUMAKRAS all delivered double-digit growth.

Not every product performed as strongly. Sales of Prolia and XGEVA declined sharply as biosimilar competition intensified, while Otezla, Enbrel and Kyprolis also posted lower sales.

Looking ahead, Amgen reaffirmed its full-year 2026 outlook, expecting revenue between $38.2 billion and $39.4 billion and non-GAAP earnings per share of $22.30 to $23.50. The company also continues advancing its late-stage pipeline, including obesity candidate MariTide and several Phase 3 programs, while expanding existing medicines into new indications.

Investors appeared encouraged by the combination of double-digit revenue growth, continued strength across Amgen's newer products, improving cash generation, and management's confidence in sustaining long-term growth despite increasing biosimilar competition across parts of its mature portfolio.

💬

WS Investor 08-04-26

Amgen (NASDAQ:AMGN) will report its first quarter 2026 financial results on Thursday, April 30, 2026, after the close of the U.S. markets.

💬

The Investor 04-26-26

Amgen announced positive Phase 3 results for a new subcutaneous version of its thyroid eye disease treatment, TEPEZZA.

The study met its primary endpoint, with about 77% of patients achieving a significant reduction in eye bulging (proptosis), compared to roughly 20% in the placebo group. The treatment also demonstrated clinically meaningful improvements across multiple secondary measures, including symptom severity and quality of life.

The subcutaneous (under-the-skin) delivery method showed comparable effectiveness to the existing intravenous version, while offering a more convenient administration option for patients.

Amgen said the safety profile was consistent with previous data, with mostly mild-to-moderate side effects.

The company highlighted that this development could expand access to treatment for thyroid eye disease, a rare and potentially vision-threatening autoimmune condition.
PRNewswire

💬

Global Finance News 04-07-26

Dividend Growth Stocks: Amgen, Inc. (AMGN) Dividend Stock Analysis

Your source for finding the best dividend growth stocks

(dividend-growth-stocks.com)

💬

The Investor 03-13-26

Amgen (NASDAQ:AMGN) announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend will be paid on June 5, 2026, to all stockholders of record as of the close of business on May 15, 2026.

💬

Global Finance News 03-06-26

Amgen announced that the European Commission has approved UPLIZNA® (inebilizumab) as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are anti-AChR or anti-MuSK antibody positive. It is the first and only CD19-targeted therapy approved in Europe for these patients.

The approval is based on the Phase 3 MINT trial, which showed a statistically significant improvement in MG-ADL and QMG scores at Week 26 versus placebo. UPLIZNA delivered a 1.9-point greater reduction in MG-ADL scores (p<0.0001) and a 2.5-point greater reduction in QMG scores (p=0.0002) in the combined population. The therapy is administered after two initial infusions, followed by maintenance dosing every six months.

gMG is a rare, chronic autoimmune disease that causes fluctuating muscle weakness and can severely impact daily functioning. The approval expands UPLIZNA’s European indications, which already include IgG4-related disease and neuromyelitis optica spectrum disorder.

PR Newswire

💬

WS Investor 02-13-26

Amgen disclosed that it has agreed with Kyowa Kirin to terminate their License and Collaboration Agreement dated June 1, 2021. The decision was formalized through a Termination Agreement signed on January 30, 2026, and the termination will become effective once the required regulatory approval is obtained. No additional financial details were disclosed in the filing.

💬

Global Finance News 01-30-26

Amgen Acquires Dark Blue Therapeutics to Strengthen Oncology Pipeline

Amgen announced the acquisition of Dark Blue Therapeutics in a deal valued at up to $840 million, adding a differentiated investigational therapy targeting acute myeloid leukemia (AML). The acquired program focuses on a first-in-class small molecule designed to degrade the MLLT1/3 proteins that drive certain AML subtypes, with promising preclinical activity.

Amgen said Dark Blue will be integrated into its research organization, reinforcing early oncology discovery and targeted protein degradation efforts. The company highlighted the potential for the therapy to address treatment resistance and improve remission durability in a cancer with significant unmet need.

Source: Amgen press release via PR Newswire, January 6, 2026

💬

The Investor 01-06-26

NASDAQ:AMGNFollow

Dividend Growth Stocks: Amgen, Inc. (AMGN) Dividend Stock Analysis

NASDAQ:AMGN